Clinical Trial Update: LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating LY2157299 Monohydrate in combination with radiotherapy for metastatic breast cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• LY2157299 Monohydrate (galunisertib monohydrate)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-12-09